Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade
Endocrinopathies, such as thyroid autoimmunity, are common among patients treated with immune checkpoint inhibitors. Here, by using a polygenic risk score (PRS) derived from a hypothyroidism GWAS, the authors show that cancer patients with high PRS are at increased risk of atezolizumab (anti-PD-L1)-...
Guardado en:
Autores principales: | Zia Khan, Christian Hammer, Jonathan Carroll, Flavia Di Nucci, Sergio Ley Acosta, Vidya Maiya, Tushar Bhangale, Julie Hunkapiller, Ira Mellman, Matthew L. Albert, Mark I. McCarthy, G. Scott Chandler |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c4d618dc88c448e799c4accf705c951a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
por: Shohei Koyama, et al.
Publicado: (2016) -
PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
por: Qi Peng, et al.
Publicado: (2020) -
Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes
por: Robert A. Szczepaniak Sloane, et al.
Publicado: (2021) -
PD-1 immune checkpoint blockade may be viable for the prevention and treatment of elderly patients with POCD [Letter]
por: Wei P, et al.
Publicado: (2019) -
Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade
por: Victoria Klepsch, et al.
Publicado: (2018)